Rapid progress in cultivated meat
Cultivated meat is expected to reach price parity with conventional meat sooner than previously forecast, according to a new analysis by technology foresight specialist GetFocus.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1306 entries already.
Entries by Thomas Gabrielczyk
Mabion launches €500,000 services contest to support oncology breakthroughs
/in News/by Thomas GabrielczykLodz-based CDMO Mabion SA has launched a €500,000 oncology services contest at BIO International Convention 2025, aimed at accelerating the development of recombinant protein-based cancer therapies. The contest will culminate at CPHI Worldwide in Frankfurt this October, spotlighting promising biotechs ready to scale their innovation.
French Afyren starts production of bio-acids – CEO in interview
/in News/by Thomas GabrielczykAFYREN’s first biorefinery, AFYREN NEOXY, has reached continuous production, marking a key step toward large-scale commercialisation of its bio-based acids. The plant will now ramp up output and fulfill long-term contracts across key sectors like nutrition, cosmetics, and life sciences. European Biotech News talked to CEO Nicolas Sordet about the long and winding road to sucess.
GEA to open food biotech pilot-scale facility in USA
/in News/by Thomas GabrielczykGEA has launched its second Food Application and Technology Center (ATC) globally in the US, to target the largest consumer market for cellular agriculture. The facility features advanced bioreactors and precision fermentation systems that enable companies to test and optimise processes for producing alternative proteins and other novel food products.
The smell of food makes you feel full
/in News/by Thomas GabrielczykLose weight without expensive obesity pills? The discovery of a direct link between olfactory receptors and areas of the brain that signal satiety makes this seem possible, initially in mice.
SpliceBio SL secures US$135m in Series B financing
/in News/by Thomas GabrielczykSpliceBio SL has baged US$135m in a Series B financing co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors The Barcelona-based company will use the proceeds to advance SB-007 in Stargardt disease and expand its pipeline of meds that regulate splicing.
Mosanna Therapeutics bags $80m in Series A round
/in News/by Thomas GabrielczykObstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118.
Spanish BIO-CAT cluster starts new ATMP accelerator
/in News/by Thomas GabrielczykThe Spanish BIO-CAT cluster has launched a new accelerator called ATMP Catalyst, which will support six preclinical gene and cell therapy projects per year in each of three annual calls to support translation into clinical development.
Big deal: Amphistar goes transatlantic
/in News/by Thomas GabrielczykBelgian micriobial fermentation specialist AmphiStar NV has partnered with US plant-based ingredient heavyweight Kensing to market its biosurfactants in the US, using locally-produced feedstocks. Amphistar’s biosurfactants are an alternative to palm oil made surfactants that are 25% of the current US$20bn surfactant market.
Pharma industry calls EU pharma package counterproductive
/in News/by Thomas GabrielczykPharmaceutical associations have responded with sharp criticism to the adoption of the revised general pharmaceutical legislation by the EU Council of Ministers in the form of a directive and a regulation. They argue that the measures are not suitable for bringing Europe back to the forefront of pharmaceutical research and will make the EU an unattractive location for investment.